美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Braveheart Bio

28.01

+0.50501.84%

成交量：9.34萬

成交額：264.55萬

市值：19.79億

市盈率：-24.65

高：29.25

開：28.29

低：27.50

收：27.50

52周最高：32.00

52周最低：24.61

股本：7,065.28萬

流通股本：1,875.00萬

量比：0.49

換手率：0.50%

股息：- -

股息率：- -

每股收益(TTM):-1.1360

每股收益(LYR):-3.9270

淨資產收益率：--

總資產收益率：--

市淨率：-25.24

市盈率(LYR):-7.13

資料載入中...

總覽公司新聞資訊公告

新聞稿：Braveheart Bio 宣佈擴大規模首次公開募股完成，並完全行使承銷商超額配股權

市場快訊——美股行情動態-Braveheart Bio、Paysign、Hertz Global

異動解讀 | IPO首日表現強勁，Braveheart Bio盤中大漲67.78%

美股異動 | 心血管藥企Braveheart Bio(BRVE.US)登陸美股市場開盤後股價升逾75%

美股異動 | 心血管藥企Braveheart Bio(BRVE.US)登陸美股市場開盤後股價升逾75%

Braveheart Bio在將IPO規模擴大至3.83億美元后，有望在紐約首秀中股價大漲

生物科技IPO熱潮持續!心血管藥企Braveheart(BRVE.US)募資擴大至3.825億美元，發行價突破指引上限

Braveheart Bio(BRVE.US)IPO定價15-17美元/股，擬募資3億美元推進心血管藥物全球三期臨床

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/BRVE/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BRVE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":28.005,"timestamp":1787686349797,"preClose":27.5,"halted":0,"volume":93373,"delay":0,"changeRate":0.01836363636363633,"floatShares":18750000,"shares":70652838,"eps":-1.136,"marketStatus":"交易中","change":0.505,"latestTime":"08-25 15:32:46 EDT","open":28.29,"high":29.25,"low":27.5,"amount":2645453.1733,"amplitude":0.063636,"askPrice":27.99,"askSize":11,"bidPrice":27.7,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.136,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":27.5,"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.5,"latestTime":"19:57 EDT","volume":49,"amount":1347,"timestamp":1787615879670,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.493917},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","floatShares":18750000,"roa":"--","roe":"--","lyrEps":-3.927011,"volumeRatio":0.493917,"shares":70652838,"dividePrice":0,"high":29.25,"amplitude":0.063636,"preClose":27.5,"low":27.5,"week52Low":24.61,"pbRate":"-25.24","week52High":32,"institutionHeld":0,"latestPrice":28.005,"committee":0.801802,"eps":-1.136,"divideRate":0,"volume":93373,"delay":0,"ttmEps":-1.136,"open":28.29,"prevYearClose":18,"prevWeekClose":27.58,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":26.75,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRVE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRVE\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRVE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRVE","date":"2026-08-24","current":-24.207746,"percent":0.307692,"low":-23.993466,"twenty":-22.435171,"median":-21.774071,"eighty":-20.463228,"high":-12.297967,"avg":-20.644913,"sd":3.256461,"marketCap":1769778951},"quantilePoints":[{"date":"2026-08-07","current":-22.904964,"twenty":-19.277064,"median":-13.835213,"eighty":-12.912865,"marketCap":1837733965},{"date":"2026-08-14","current":-20.770344,"twenty":-22.55018,"median":-20.842324,"eighty":-16.302149,"marketCap":1666466982},{"date":"2026-08-21","current":-21.930028,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"marketCap":1759511923},{"date":"2026-08-24","current":-22.057993,"twenty":-22.435171,"median":-21.774071,"eighty":-20.463228,"marketCap":1769778951}],"updateTime":1787658024217},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRVE\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1171302218","title":"新聞稿：Braveheart Bio 宣佈擴大規模首次公開募股完成，並完全行使承銷商超額配股權","url":"https://stock-news.laohu8.com/highlight/detail?id=1171302218","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171302218?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:09","pubTimestamp":1786133340,"startTime":"0","endTime":"0","summary":"旧金山，2026年8月7日——Braveheart Bio, Inc.是一家临床阶段的生物制药公司，致力于开发针对肥厚型心肌病及其他严重心血管疾病的下一代疗法。该公司今日宣布，其扩大的首次公开募股已完成。此次发行总计24,437,500股普通股，每股发行价为18.00美元，且承销商已完全行使了购买额外3,187,500股的选择权。所有普通股均由Braveheart Bio提供。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0203345920.USD","LU0289739343.SGD","BK4533","HCM","LU0289961442.SGD","IE000M9KFDE8.USD","LU0154245756.USD","BK4531","LU0069063385.USD","LU0689626769.HKD","BRVE","CMI","LU0154245673.USD","LU2463526074.USD","BK4585","MADE","LU0124676726.USD","BK4007","LU0057025933.USD","BK4567","LU0203347892.USD","IPOS","LU0472753341.HKD","LU0511384066.AUD","BK4149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657597666","title":"市場快訊——美股行情動態-Braveheart Bio、Paysign、Hertz Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2657597666","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657597666?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 01:45","pubTimestamp":1786038322,"startTime":"0","endTime":"0","summary":".N美国东部时间13:30，道琼斯工业平均指数.DJI下跌0.85%，报53,886.07点；标普500指数.SPX下跌0.28%，报7,701.81点；纳斯达克综合指数.IXIC下跌0.10%，报26,337.82点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL4T44328R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRMB","PAYC","GBFH","SRE","HWM","SRRK","WDC","FRT","HTZ","ZTS","KVUE","PH","MTSI","CELH","INSM","U","CEG","FIG","CHYM","LCLN","SNDK","KDP","FISV","SMR","TPG","IOVA","FOUR","BRVE","RL","BDX","SPCX","RDVT","MRNA","SITM","NVAX","RXO","EPAM","MAC","PZZA","VTRS","RCBC","DDOG","UWMC","ROOT","APP","VCTR","LNG","BLLN"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1138238457","title":"異動解讀 | IPO首日表現強勁，Braveheart Bio盤中大漲67.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138238457","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138238457?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:52","pubTimestamp":1786035174,"startTime":"0","endTime":"0","summary":"心血管药物开发商Braveheart Bio今日在纳斯达克首日上市交易，盘中股价大涨67.78%，引发市场广泛关注。Braveheart Bio总部位于加州旧金山，是一家处于临床后期的生物制药公司，专注于开发肥厚型心肌病及其他严重心血管疾病的创新疗法。在2026年生物科技IPO热潮的背景下，Braveheart Bio的成功上市进一步彰显了市场对创新药企的强劲信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656478","title":"美股異動 | 心血管藥企Braveheart Bio(BRVE.US)登陸美股市場 開盤後股價升逾75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656478","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656478?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:00","pubTimestamp":1786032000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，心血管药企Braveheart Bio(BRVE.US)登陆美股市场，截至发稿，该股涨超75%，报31.405美元。IPO价格为18美元。Braveheart Bio成立于2024年，是一家处于临床后期的生物制药公司，专注于开发肥厚型心肌病(HCM)及其他严重心血管疾病的创新疗法。公司的核心候选药物BHB-1893(亦称HRS-1893)是一种口服小分子心肌肌球蛋白抑制剂，通过特异性抑制心肌肌球蛋白ATP酶活性，使心肌收缩性能正常化，减少左心室肥厚并改善舒张期顺应性。该药物于2025年9月从中国江苏恒瑞医药获得全球(除大中华区外)独家许可授权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656475","title":"美股異動 | 心血管藥企Braveheart Bio(BRVE.US)登陸美股市場 開盤後股價升逾75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656475?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:00","pubTimestamp":1786032000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657618658","title":"Braveheart Bio在將IPO規模擴大至3.83億美元后，有望在紐約首秀中股價大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2657618658","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657618658?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 22:50","pubTimestamp":1786027821,"startTime":"0","endTime":"0","summary":"BUZZ-Braveheart Bio在将IPO规模扩大至3.83亿美元后，有望在纽约首秀中股价大涨8月6日-** 药物开发商Braveheart Bio（BRVE.O）在将美国首次公开募股（IPO）规模扩大至3.825亿美元后，其纳斯达克首日上市开盘价有望高于发行价** 该股最新显示开盘价为每股25美元，高于18美元的发行价** 总部位于加利福尼亚州旧金山的BRVE在规模扩大的首次公开募股（(l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL4T4431TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SF","LU1791807156.HKD","LU2237443622.USD","LU1894683264.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0868494708.USD","LU0096364046.USD","LU2237443382.USD","LU1894683348.USD","BK4550","IE0004086264.USD","LU1868836591.USD","LU2471134523.USD","LU0061475181.USD","IE0004091025.USD","LU2265009873.SGD","LU0868494617.USD","BRVE","LU2750360641.GBP","LU2471134952.CNY","IE00B19Z3581.USD","IE00BSNM7G36.USD","LU2237438978.USD","BK4516","IE0034235188.USD","LU0251131958.USD","LU2237443465.HKD","LU2750360997.AUD","LU2237443895.HKD","GSX","LU0345770308.USD","LU0942090050.USD","LU0742534661.SGD","LU2471134796.USD","LU1804176565.USD","LU1868836914.USD","LU2471134879.HKD","BK4552","LU1668664300.SGD","LU2237443978.SGD","LU0345770993.USD","BK4127","LU0048573561.USD","LU1868836757.USD","LU2237443549.SGD","BK4588","BK4533","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657070685","title":"生物科技IPO熱潮持續!心血管藥企Braveheart(BRVE.US)募資擴大至3.825億美元，發行價突破指引上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2657070685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657070685?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 16:28","pubTimestamp":1786004901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SYNB","IEIH","GDOC","IBBJ","MEDX","FRHC","XBI","BK4588","LNGR","KCE","AGNG","BK4585","BK4127","BK4581","REDS","IPOS","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655330649","title":"Braveheart Bio(BRVE.US)IPO定價15-17美元/股，擬募資3億美元推進心血管藥物全球三期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2655330649","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655330649?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 14:34","pubTimestamp":1785479661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BRVE","UUP","IPOS","UDN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}